Cargando…
IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models
We report the synthesis and preliminary characterization of IODVA1, a potent small molecule that is active in xenograft mouse models of Ras-driven lung and breast cancers. In an effort to inhibit oncogenic Ras signaling, we combined in silico screening with inhibition of proliferation and colony for...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067412/ https://www.ncbi.nlm.nih.gov/pubmed/32163428 http://dx.doi.org/10.1371/journal.pone.0229801 |
_version_ | 1783505396620591104 |
---|---|
author | Gasilina, Anjelika Premnauth, Gurdat Gurjar, Purujit Biesiada, Jacek Hegde, Shailaja Milewski, David Ma, Gang Kalin, Tanya V. Merino, Edward Meller, Jarek Seibel, William Cancelas, José A. Vinnedge, Lisa Privette Nassar, Nicolas N. |
author_facet | Gasilina, Anjelika Premnauth, Gurdat Gurjar, Purujit Biesiada, Jacek Hegde, Shailaja Milewski, David Ma, Gang Kalin, Tanya V. Merino, Edward Meller, Jarek Seibel, William Cancelas, José A. Vinnedge, Lisa Privette Nassar, Nicolas N. |
author_sort | Gasilina, Anjelika |
collection | PubMed |
description | We report the synthesis and preliminary characterization of IODVA1, a potent small molecule that is active in xenograft mouse models of Ras-driven lung and breast cancers. In an effort to inhibit oncogenic Ras signaling, we combined in silico screening with inhibition of proliferation and colony formation of Ras-driven cells. NSC124205 fulfilled all criteria. HPLC analysis revealed that NSC124205 was a mixture of at least three compounds, from which IODVA1 was determined to be the active component. IODVA1 decreased 2D and 3D cell proliferation, cell spreading and ruffle and lamellipodia formation through downregulation of Rac activity. IODVA1 significantly impaired xenograft tumor growth of Ras-driven cancer cells with no observable toxicity. Immuno-histochemistry analysis of tumor sections suggests that cell death occurs by increased apoptosis. Our data suggest that IODVA1 targets Rac signaling to induce death of Ras-transformed cells. Therefore, IODVA1 holds promise as an anti-tumor therapeutic agent. |
format | Online Article Text |
id | pubmed-7067412 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-70674122020-03-23 IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models Gasilina, Anjelika Premnauth, Gurdat Gurjar, Purujit Biesiada, Jacek Hegde, Shailaja Milewski, David Ma, Gang Kalin, Tanya V. Merino, Edward Meller, Jarek Seibel, William Cancelas, José A. Vinnedge, Lisa Privette Nassar, Nicolas N. PLoS One Research Article We report the synthesis and preliminary characterization of IODVA1, a potent small molecule that is active in xenograft mouse models of Ras-driven lung and breast cancers. In an effort to inhibit oncogenic Ras signaling, we combined in silico screening with inhibition of proliferation and colony formation of Ras-driven cells. NSC124205 fulfilled all criteria. HPLC analysis revealed that NSC124205 was a mixture of at least three compounds, from which IODVA1 was determined to be the active component. IODVA1 decreased 2D and 3D cell proliferation, cell spreading and ruffle and lamellipodia formation through downregulation of Rac activity. IODVA1 significantly impaired xenograft tumor growth of Ras-driven cancer cells with no observable toxicity. Immuno-histochemistry analysis of tumor sections suggests that cell death occurs by increased apoptosis. Our data suggest that IODVA1 targets Rac signaling to induce death of Ras-transformed cells. Therefore, IODVA1 holds promise as an anti-tumor therapeutic agent. Public Library of Science 2020-03-12 /pmc/articles/PMC7067412/ /pubmed/32163428 http://dx.doi.org/10.1371/journal.pone.0229801 Text en © 2020 Gasilina et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Gasilina, Anjelika Premnauth, Gurdat Gurjar, Purujit Biesiada, Jacek Hegde, Shailaja Milewski, David Ma, Gang Kalin, Tanya V. Merino, Edward Meller, Jarek Seibel, William Cancelas, José A. Vinnedge, Lisa Privette Nassar, Nicolas N. IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models |
title | IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models |
title_full | IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models |
title_fullStr | IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models |
title_full_unstemmed | IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models |
title_short | IODVA1, a guanidinobenzimidazole derivative, targets Rac activity and Ras-driven cancer models |
title_sort | iodva1, a guanidinobenzimidazole derivative, targets rac activity and ras-driven cancer models |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7067412/ https://www.ncbi.nlm.nih.gov/pubmed/32163428 http://dx.doi.org/10.1371/journal.pone.0229801 |
work_keys_str_mv | AT gasilinaanjelika iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT premnauthgurdat iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT gurjarpurujit iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT biesiadajacek iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT hegdeshailaja iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT milewskidavid iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT magang iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT kalintanyav iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT merinoedward iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT mellerjarek iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT seibelwilliam iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT cancelasjosea iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT vinnedgelisaprivette iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels AT nassarnicolasn iodva1aguanidinobenzimidazolederivativetargetsracactivityandrasdrivencancermodels |